New weight loss pill outperforms rivals but causes side effects | 7NEWS
A new daily weight loss pill called orforglipron, manufactured by Eli Lilly, has demonstrated superior results to Wegovy in a clinical trial of over 1,500 adults with type 2 diabetes across five countries. After 12 months, participants taking orforglipron experienced 6-8% weight loss compared to 4-5% with oral semaglutide, along with bigger drops in average blood sugar levels. However, orforglipron caused more severe gastrointestinal side effects including vomiting and diarrhoea, leading up to 10% of trial participants to discontinue use, and the medication is still awaiting regulatory approval in Australia.
Subscribe and set 🔔 » https://7news.link/YTSubscribe |
For the latest Australian news and breaking news alerts, connect with 7NEWS online:
Visit » https://7news.com.au
7Plus » https://7plus.com.au/
7NEWS Podcast » https://open.spotify.com/user/dm9fk9hzoe68ibpttheragdgi
Facebook » https://www.facebook.com/7NewsAustralia
TikTok » https://www.tiktok.com/@7newsaustralia
Instagram » https://www.instagram.com/7newsaustralia/
X » https://x.com/7NewsAustralia
7NEWS combines the trusted and powerful news brands including Sunrise, The Morning Show, Spotlight and 7NEWS.com.au, delivering unique, engaging and continuous coverage on the issues that matter most to Australians. Watch 7 News Australia full broadcasts and full episodes at 6pm and weekdays at 12pm and 4pm on Channel 7 and 7plus.
#BREAKINGNEWS #7NEWS
